doi: 10.1161/CIRCULATIONAHA.105.583484
(Circulation. 2005;112:2759-2761.)
© 2005 American Heart Association, Inc.
Editorial |
Prevention of Restenosis by Systemic Drug Therapy
Back to the Future?
From Deutsches Herzzentrum and 1. Medizinische Klinik, Technische Universität Munich, Germany.
Correspondence to Albert Schömig, MD, Deutsches Herzzentrum and 1. Medizinische Klinik, Technische Universität, Lazarettstraße 36, 80636 Munich, Germany. E-mail aschoemig@dhm.mhn.de
Key Words: Editorials • coronary disease • angioplasty • restenosis • stents
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
 |
Introduction |
|---|
In this issue of Circulation, 2 studies report a positive outcome in patients who received oral pharmacotherapy for the prevention of restenosis after stent placement. In the randomized, double-blind, placebo-controlled Cilostazol for Restenosis Trial (CREST) trial,1 patients were given cilostazol, a phosphodiesterase 3 inhibitor with antithrombotic2 and antiproliferative3 properties, for 6 months starting immediately after implantation of a bare-metal stent in a de novo target lesion. Minimal lumen diameter, the primary end point of this study, which comprised 705 patients, was larger among patients treated with cilostazol than among those who received placebo. Other angiographic but not clinical outcomes were also more favorable among patients assigned to the active treatment arm.
Articles pp 2792 and 2826
The second study investigated the effect of a 6-month treatment with the thiazolidinedione pioglitazone on neointima formation measured by intravascular ultrasound 6 months after bare-metal stent implantation for de novo coronary artery lesions.4 In this small study, which comprised a total of 50 nondiabetic patients, neointima formation was significantly reduced among patients treated with pioglitazone compared with those who received placebo. Similarly, angiographic and clinical measures of restenosis were better among patients assigned to pioglitazone treatment. Although potential beneficial effects of thiazolidinedione regarding the prevention of neointima formation include antiinflammatory5 and antiproliferative effects,6 the exact mechanism by which pioglitazone led to a reduction of neointima formation among patients included in this study remains elusive.
The findings of these studies add to the existing evidence on the use of systemic pharmacological approaches to prevent
This article has been cited by other articles:
 |
|
 |
|
  R. Baetta, A. Granata, M. Canavesi, N. Ferri, L. Arnaboldi, S. Bellosta, P. Pfister, and A. Corsini Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yau, P. Molnar, M. C. Moon, S. Buhay, J. P. Werner, K. Molnar, L. Saward, D. Del Rizzo, and P. Zahradka meta-Iodobenzylguanidine, an Inhibitor of Arginine-Dependent Mono(ADP-ribosyl)ation, Prevents Neointimal Hyperplasia J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 717 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kastrati and A. Schomig Drug-Eluting Stents: Is Their Future as Bright as Their Past? J. Am. Coll. Cardiol., July 10, 2007; 50(2): 146 - 148. [Full Text] [PDF]
|
|
|
|
|
|
T. Adriaenssens, J. Mehilli, R. Wessely, G. Ndrepepa, M. Seyfarth, A. Wieczorek, B. Blaich, R. Iijima, J. Pache, A. Kastrati, et al. Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?: Results of the ISAR-PEACE Randomized Trial J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1265 - 1271. [Abstract] [Full Text] [PDF]
|
|